Major advances in oncology treatments, environmental health links, and expanded pharmacy prescribing authority mark significant developments across cancer care, immunological diseases, and healthcare delivery.

Breast cancer patients can now safely skip axillary lymph node dissection based on the largest randomized trial to date, which demonstrated noninferior survival outcomes with better arm morbidity results for those who avoided the procedure.

Tafasitamab combined with lenalidomide and R-CHOP is poised for approval in frontline diffuse large B-cell lymphoma treatment, though uncertainty remains about its role as bispecific antibodies enter the therapeutic landscape.

GammaTile brachytherapy shows promise for treating large brain metastases after resection, with a phase 3 trial demonstrating improved outcomes over standard stereotactic radiation, though the striking overall survival benefit warrants further investigation.

Traffic pollution exposure has been linked to increased chronic rhinosinusitis risk, suggesting that different pollutants may eventually require tailored treatment approaches for this condition.

Guselkumab becomes the sole IL-23 inhibitor proven to halt structural damage progression in patients with active psoriatic arthritis, expanding treatment options for this debilitating condition.

Two longitudinal studies provide reassuring safety data for high-efficacy multiple sclerosis medications during pregnancy, with no adverse signals detected from prenatal exposure to these drugs.

England's £340 million pharmacy funding deal expands independent prescribing authority for pharmacists across more conditions, though the National Pharmacy Association warns it falls short of addressing a £2.5 billion broader funding deficit.

Mepolizumab receives NICE recommendation for uncontrolled eosinophilic COPD, becoming the second biologic approved this year alongside dupilumab and offering patients alternatives to triple therapy regimens.